Apoptosis News and Research

RSS

Apoptosis is programmed cell death, the body's normal method of disposing of damaged, unwanted, or unneeded cells.

Pre-clinical data of BiTE antibody technology published in PNAS

Micromet, Inc., today announced the publication of pre-clinical data in the Proceedings of the National Academy of Sciences, demonstrating the potency of new product candidates based on the Company's proprietary BiTE antibody technology. BiTE antibodies are a new class of agents designed to harness a patient's T cells to kill cancer cells.

1 Jul 2010

Key mechanism present in virgin olive oil protects body against breast cancer: Researchers

Researchers at Universitat Autònoma de Barcelona, led by Dr Eduard Escrich, have discovered a key mechanism by which virgin olive oil, in contrast to other vegetable oils, protects the body against breast cancer.

30 Jun 2010

Calistoga Pharmaceuticals closes $40 million Series C financing

Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced it has closed a $40 million Series C financing. The financing was led by Quogue Capital, LLC along with existing investors Alta Partners, Amgen Ventures, Frazier Healthcare and Three Arch Partners and new investor Latterell Venture Partners.

30 Jun 2010

Data published in Cancer Research demonstrates proof of concept for Mirna's tumor suppressor miRNAs

Mirna Therapeutics announced today publication of new results in the journal Cancer Research demonstrating proof of concept that the systemic delivery of tumor suppressor microRNAs (miRNA) inhibits tumor growth by restoring the proper regulatory pathways required for cell cycle arrest and apoptosis.

30 Jun 2010

EpiCept requests FDA priority review of Ceplene NDA for AML

EpiCept Corporation announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Ceplene® (histamine dihydrochloride). EpiCept is seeking approval for Ceplene, administered concomitantly with low-dose interleukin-2 (IL-2), for the remission maintenance and prevention of relapse in patients with Acute Myeloid Leukemia (AML) in first complete remission.

29 Jun 2010

EpiCept signs definitive agreements for purchase of 6.1M shares of common stock

EpiCept Corporation announced today that it entered into definitive agreements for the purchase of approximately 6.1 million shares of its common stock at $1.10 per share, five year warrants to purchase up to approximately 4.6 million shares of common stock at an exercise price of $1.57 per share exercisable beginning December 30, 2010 and one year warrants to purchase up to approximately 6.1 million shares of common stock at an exercise price of $1.57 per share exercisable beginning December 30, 2010.

28 Jun 2010

Sanofi-aventis' Phase I clinical trial with SAR650984 triggers $1M milestone payment to ImmunoGen

ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products, today announced that sanofi-aventis has initiated a Phase I clinical trial with SAR650984, an investigational antibody that targets cancer cells expressing the CD38 protein antigen. This event triggers a $1 million milestone payment to ImmunoGen.

25 Jun 2010

CXCL12/CXCR4 chemokine axis plays a critical role in pathogenesis of ulcerative colitis

Ulcerative colitis (UC) is characterized by frequent diarrheal attacks and anal bleeding. Histologic characteristics of UC are the invasion of the crypt epithelium and lamina propria by peripheral blood mononuclear cells (PBMCs), disruption of the epithelial lining, and consequently mucosal ulceration and crypt abscess formation in the bowel wall.

25 Jun 2010

Mice treated with XOMA 052 experiences improvement in measures associated with diabetes: Endocrinology

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced the publication of data from a mouse model of diet-induced obesity in the June, 2010 edition of the journal Endocrinology. The data showed that mice treated with XOMA 052 both prophylactically and therapeutically experienced improvement in measures associated with diabetes and cardiovascular disease including reduction in glycosylated hemoglobin levels, improvement in glucose control, improved beta-cell survival and function, and a reduction in total cholesterol without reduction in high density lipoprotein.

23 Jun 2010

Semafore's SF1126 peptidic prodrug demonstrates clinical activity in chronic lymphocytic leukemia

Semafore Pharmaceuticals today announced the presentation of preliminary clinical data demonstrating that SF1126 has clinical activity in chronic lymphocytic leukemia (CLL). SF1126 is a novel peptidic prodrug that converts to LY294002, one of the most widely studied small molecule inhibitors of both phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR). The results were presented at Cambridge Healthtech Institute's 8th Annual Next-Gen Kinase Inhibitors Oncology & Beyond Conference being held June 21-23, 2010, in Cambridge, Massachusetts.

22 Jun 2010

Prototype drug blocks MCL-1 protein that helps tumors survive treatment: Scientists

Scientists at Dana-Farber Cancer Institute have found a way to disable a common protein that often thwarts chemotherapy treatment of several major forms of cancer.

21 Jun 2010

Bioniche announces issuance of new patents for MCC, Oligonucleotide technology platforms

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced the issuance of a number of patents for its proprietary Mycobacterial Cell Wall-DNA Complex (MCC) composition and its Oligonucleotide technology platform.

18 Jun 2010

Researchers assess effect of MDs on cardiac and endothelial cell proliferation, survival

A research team from McGill University (Canada) report a beneficial effect on cardiac function in mouse models when implanted monocytes - a type of white blood cell that is part of the immune system - helped preserve cardiac function following a heart attack (myocardial infarction).

17 Jun 2010

Deuterium depletion symposium focusses on oncotherapy, anticancer, diabetes, anti-aging research

1st International Symposium on Deuterium Depletion was held on 13-14 May 2010 in Budapest, Hungary. The conference programme focused on the advances in the research and clinical application of deuterium depletion, its present and future role in anticancer research and oncotherapy, diabetes research and anti-aging.

17 Jun 2010

Symposium explores new understanding of mitochondrial function, cellular bioenergetics in cancer research

Seahorse Bioscience, Inc., the leader in instruments for assessing cellular bioenergetics, recently organized a symposium on Cancer and Mitochondrial Function featuring Douglas Green, Ph.D., from St. Jude Children's Hospital; Navdeep S. Chandel, Ph.D., from Northwestern Medical School; and Nicholas C. Denko, Ph.D., from Stanford University School of Medicine.

17 Jun 2010

BIOCIUS Life Sciences, BlueSky Biotech collaborate to offer Sirtuin pre-validated assay solution

BIOCIUS Life Sciences Inc., developers of the RapidFire® high-throughput mass spectrometry system, and BlueSky Biotech, service provider of discovery biologicals, today announced their collaboration to offer the industry's only Sirtuin (SIRT, silent mating type information regulation homolog) enzyme preparations fully-validated in a label-free functional assay.

16 Jun 2010

EpiCept's common stock included on a list of preliminary additions to Russell Microcap Index

EpiCept Corporation announced today that the Company's common stock has been included on a list of preliminary additions to the Russell Microcap Index posted by Russell Investments on June 11, 2010 on www.russell.com. These changes are expected to go into effect after the close of trading on Friday, June 25, 2010.

15 Jun 2010

Sulindac shuts down cancer cell growth, initiates cell death: Study

Without knowing exactly why, scientists have long observed that people who regularly take non-steroidal anti-inflammatory drugs like aspirin have lower incidences of certain types of cancer. Now, in a study appearing in Cancer Cell on June 15, investigators at Sanford-Burnham Medical Research Institute and their colleagues have figured out how one NSAID, called Sulindac, inhibits tumor growth.

15 Jun 2010

Calistoga Pharmaceuticals presents CAL-101 PI3K inhibitor data at European Hematology Association Congress

Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today presented preclinical and clinical data on CAL-101, the Company's oral, delta selective PI3K inhibitor at the 15th Congress of the European Hematology Association in Barcelona, Spain.

14 Jun 2010

Study demonstrates p53 protein becomes activated during gamete formation

Protein p53 is known as the guardian of the genome since it is basic for the genome's integrity by preventing the accumulation of mutations originating either by the cell's own mechanisms or by the action of external agents.

11 Jun 2010

Apoptosis News and Research

Pre-clinical data of BiTE antibody technology published in PNAS

Key mechanism present in virgin olive oil protects body against breast cancer: Researchers

Calistoga Pharmaceuticals closes $40 million Series C financing

Data published in Cancer Research demonstrates proof of concept for Mirna's tumor suppressor miRNAs

EpiCept requests FDA priority review of Ceplene NDA for AML

EpiCept signs definitive agreements for purchase of 6.1M shares of common stock

Sanofi-aventis' Phase I clinical trial with SAR650984 triggers $1M milestone payment to ImmunoGen

CXCL12/CXCR4 chemokine axis plays a critical role in pathogenesis of ulcerative colitis

Mice treated with XOMA 052 experiences improvement in measures associated with diabetes: Endocrinology

Semafore's SF1126 peptidic prodrug demonstrates clinical activity in chronic lymphocytic leukemia

Prototype drug blocks MCL-1 protein that helps tumors survive treatment: Scientists

Bioniche announces issuance of new patents for MCC, Oligonucleotide technology platforms

Researchers assess effect of MDs on cardiac and endothelial cell proliferation, survival

Deuterium depletion symposium focusses on oncotherapy, anticancer, diabetes, anti-aging research

Symposium explores new understanding of mitochondrial function, cellular bioenergetics in cancer research

BIOCIUS Life Sciences, BlueSky Biotech collaborate to offer Sirtuin pre-validated assay solution

EpiCept's common stock included on a list of preliminary additions to Russell Microcap Index

Sulindac shuts down cancer cell growth, initiates cell death: Study

Calistoga Pharmaceuticals presents CAL-101 PI3K inhibitor data at European Hematology Association Congress

Study demonstrates p53 protein becomes activated during gamete formation

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News